See more : ROYAL HOLDINGS Co., Ltd. (8179.T) Income Statement Analysis – Financial Results
Complete financial analysis of Evotec SE (EVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evotec SE, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Sunrise Realty Trust, Inc. Common Stock When-Issued (SUNSV) Income Statement Analysis – Financial Results
- Sanford Limited (SARDY) Income Statement Analysis – Financial Results
- Metalink Ltd. (MTLK) Income Statement Analysis – Financial Results
- Quiñenco S.A. (QUINENCO.SN) Income Statement Analysis – Financial Results
- Enwell Energy plc (RGPMF) Income Statement Analysis – Financial Results
Evotec SE (EVO)
About Evotec SE
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 781.43M | 751.45M | 618.03M | 500.92M | 446.44M | 375.41M | 257.63M | 164.51M | 127.68M | 89.50M | 85.94M | 87.27M | 80.13M | 55.26M | 42.68M | 39.61M | 32.89M | 67.35M | 64.12M | 1.94M | 3.57M | 0.00 | 0.00 |
| Cost of Revenue | 606.38M | 577.38M | 466.49M | 375.18M | 313.55M | 263.39M | 175.06M | 105.95M | 89.69M | 60.12M | 54.72M | 56.24M | 45.14M | 30.92M | 24.26M | 21.98M | 24.86M | 44.40M | 42.99M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 175.05M | 174.07M | 151.54M | 125.74M | 132.89M | 112.02M | 82.57M | 58.55M | 37.99M | 29.38M | 31.22M | 31.02M | 34.99M | 24.35M | 18.42M | 17.64M | 8.02M | 22.95M | 21.13M | 1.94M | 3.57M | 0.00 | 0.00 |
| Gross Profit Ratio | 22.40% | 23.16% | 24.52% | 25.10% | 29.77% | 29.84% | 32.05% | 35.59% | 29.75% | 32.83% | 36.33% | 35.55% | 43.66% | 44.06% | 43.16% | 44.52% | 24.40% | 34.08% | 32.95% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 57.52M | 76.64M | 72.20M | 63.95M | 58.43M | 35.62M | 17.61M | 18.11M | 18.34M | 12.40M | 9.66M | 8.34M | 8.44M | 6.12M | 20.95M | 42.54M | 36.94M | 30.31M | 9.30M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 152.74M | 142.70M | 96.02M | 77.24M | 66.55M | 57.01M | 42.38M | 27.01M | 25.17M | 17.99M | 16.60M | 16.30M | 15.76M | 15.96M | 16.70M | 19.95M | 17.81M | 18.58M | 15.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 16.87M | 13.49M | 9.42M | 9.50M | 9.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 169.61M | 156.19M | 105.45M | 77.24M | 66.55M | 57.01M | 42.38M | 27.01M | 25.17M | 17.99M | 16.60M | 16.30M | 15.76M | 15.96M | 16.70M | 19.95M | 17.81M | 18.58M | 15.54M | 6.10M | 5.27M | 5.02M | 4.27M |
| Other Expenses | -4.57M | -79.62M | -67.78M | -67.21M | -66.60M | 257.00K | -209.00K | 4.00K | 263.00K | 39.00K | 16.00K | 171.00K | 1.49M | 1.80M | -3.29M | -11.87M | 149.00K | 274.00K | 614.00K | -38.30M | -41.99M | -28.93M | -17.01M |
| Operating Expenses | 222.56M | 153.22M | 109.86M | 73.98M | 58.38M | 49.22M | 43.89M | 21.81M | 40.52M | 27.24M | 27.05M | 30.72M | 30.65M | 27.17M | 38.03M | 63.13M | 57.24M | 53.75M | 36.26M | -32.20M | -36.72M | -23.91M | -12.74M |
| Cost & Expenses | 828.93M | 730.60M | 576.36M | 449.16M | 371.92M | 312.61M | 218.96M | 127.76M | 130.21M | 87.35M | 81.77M | 86.96M | 75.79M | 58.08M | 62.30M | 85.11M | 82.10M | 98.15M | 79.25M | -32.20M | -36.72M | -23.91M | -12.74M |
| Interest Income | 9.26M | 8.34M | 2.27M | 1.34M | 2.23M | 898.00K | 903.00K | 863.00K | 533.00K | 469.00K | 261.00K | 655.00K | 413.00K | 241.00K | 499.00K | 2.96M | 1.96M | 1.37M | 851.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 11.74M | 13.15M | 9.25M | 8.47M | 7.46M | 2.59M | 1.26M | 1.52M | 1.73M | 1.62M | 1.87M | 1.86M | 1.86M | 866.00K | 433.00K | 839.00K | 483.00K | 671.00K | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 92.98M | 81.66M | 67.61M | 56.06M | 48.81M | 31.29M | 20.77M | 11.89M | 11.94M | 8.54M | 9.17M | 8.82M | 6.61M | 5.51M | 4.78M | 5.13M | 8.94M | 9.61M | 16.40M | 2.14M | 2.03M | 0.00 | 0.00 |
| EBITDA | 24.13M | -86.08M | 298.41M | 75.50M | 86.77M | 105.88M | 35.50M | 45.57M | 24.93M | 5.00M | -14.07M | 4.51M | 13.90M | 9.49M | -39.61M | -70.01M | -36.08M | -22.15M | -18.44M | -67.56M | -31.12M | -23.91M | -12.74M |
| EBITDA Ratio | 3.09% | 12.53% | 15.36% | 19.76% | 27.25% | 25.25% | 22.65% | 29.87% | 7.99% | 12.50% | 15.84% | 11.40% | 17.82% | 16.76% | -40.03% | -125.03% | -109.71% | -29.29% | -0.94% | -1,452.23% | -870.96% | 0.00% | 0.00% |
| Operating Income | -47.51M | 12.50M | 27.32M | 48.52M | 62.59M | 77.46M | 37.50M | 31.34M | 11.64M | -6.38M | -21.35M | -3.20M | 5.21M | 1.72M | -42.30M | -73.21M | -58.12M | -36.76M | -32.97M | -30.26M | -33.15M | -23.91M | -12.74M |
| Operating Income Ratio | -6.08% | 1.66% | 4.42% | 9.69% | 14.02% | 20.63% | 14.55% | 19.05% | 9.12% | -7.13% | -24.84% | -3.67% | 6.50% | 3.10% | -99.10% | -184.81% | -176.72% | -54.58% | -51.42% | -1,562.82% | -927.80% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.09M | -174.81M | 195.98M | -22.72M | -6.03M | -5.46M | -11.16M | 1.61M | 851.00K | 1.22M | -2.30M | -6.55M | 49.00K | 2.15M | -21.16M | -28.20M | 1.37M | -1.46M | -20.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -80.59M | -153.96M | 236.98M | 25.81M | 56.56M | 72.00M | 26.33M | 32.95M | 12.49M | -5.16M | -23.65M | -5.01M | 5.26M | 3.87M | -44.82M | -75.97M | -54.41M | -35.98M | -35.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -10.31% | -20.49% | 38.34% | 5.15% | 12.67% | 19.18% | 10.22% | 20.03% | 9.78% | -5.76% | -27.52% | -5.75% | 6.56% | 7.00% | -105.00% | -191.78% | -165.44% | -53.41% | -55.42% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.32M | 21.70M | 21.47M | 19.56M | 19.33M | -12.06M | 2.33M | 6.11M | -4.03M | 1.82M | 1.79M | -7.49M | -1.40M | 882.00K | 678.00K | 2.32M | -6.35M | 320.00K | -4.53M | -798.91K | 96.08K | 23.90M | 12.77M |
| Net Income | -83.91M | -175.66M | 215.51M | 6.28M | 38.16M | 84.17M | 24.26M | 27.53M | 16.52M | -6.98M | -25.43M | 2.48M | 6.75M | 3.26M | -45.50M | -78.29M | -11.16M | -32.47M | -33.58M | -29.46M | -33.25M | -23.90M | -12.77M |
| Net Income Ratio | -10.74% | -23.38% | 34.87% | 1.25% | 8.55% | 22.42% | 9.42% | 16.73% | 12.94% | -7.80% | -29.59% | 2.84% | 8.42% | 5.90% | -106.59% | -197.63% | -33.92% | -48.21% | -52.38% | -1,521.56% | -930.49% | 0.00% | 0.00% |
| EPS | -0.47 | -0.99 | 1.30 | 0.04 | 0.25 | 0.57 | 0.16 | 0.20 | 0.13 | -0.05 | -0.21 | 0.02 | 0.06 | 0.03 | -0.43 | -0.82 | -0.16 | -0.49 | -0.65 | -1.36 | -37.01 | -39.97 | -40.78 |
| EPS Diluted | -0.47 | -0.99 | 1.30 | 0.04 | 0.25 | 0.57 | 0.16 | 0.20 | 0.12 | -0.05 | -0.21 | 0.02 | 0.06 | 0.03 | -0.43 | -0.82 | -0.16 | -0.49 | -0.65 | -1.36 | -37.01 | -39.97 | -40.78 |
| Weighted Avg Shares Out | 176.92M | 176.67M | 166.41M | 153.75M | 149.73M | 147.48M | 145.01M | 132.51M | 131.68M | 131.29M | 121.22M | 117.30M | 116.02M | 109.01M | 106.85M | 95.20M | 71.83M | 66.36M | 51.99M | 21.71M | 898.27K | 597.93K | 313.09K |
| Weighted Avg Shares Out (Dil) | 176.92M | 176.70M | 166.41M | 153.75M | 149.73M | 147.48M | 145.01M | 132.51M | 137.63M | 131.29M | 121.22M | 117.30M | 116.02M | 109.01M | 106.85M | 95.20M | 71.83M | 66.36M | 51.99M | 21.71M | 898.27K | 597.93K | 313.09K |
Why Is Evotec (EVO) Stock Down 33% Today?
Evotec (NASDAQ: EVO ) stock is taking a beating on Wednesday following the release of the company's earnings report for the full year of 2023! Evotec is sliding lower today alongside the company's outlook for 2024.
Evotec shares lose a third of their value on cloudy outlook
Shares of German biotech Evotec lost a third of their value on Wednesday on an uncertain outlook as it named a new chief executive.
Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth
FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M EVOTEC'S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D” AND “JUST - EVOTEC...
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024....
Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments
COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON...
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL...
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024. The Company is going to hold a conference call...
Evotec welcomes Aurélie Dalbiez as Chief People Officer
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced the appointment of Aurélie Dalbiez as the Company's new Chief People Officer ("CPO"), effective 15 June 2024. Aurélie will be...
Finding the Next Big Winners: 7 Stocks You Can Snag for Under $10
If you're on the hunt for stocks under $10, look no further. The stock market has been off to a scorching start in 2024.
3 Stocks Set to Double: Your Fast Track to 2024 Gains
The stock market is soaring right now. It might seem too late to get in, given how far momentum stocks have already run up this year.
Source: https://incomestatements.info
Category: Stock Reports